Skip to content
DataLookout
Menu

NCT04776525

Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma

StatusRecruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved at least 1 year 2 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 6 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Sep 2026 to Dec 2027
    • Eligibility criteria expanded, about 37 words
    • Study completion pushed from Sep 2036 to Dec 2037
    • Secondary endpoints: details revised at 1 of 2 entries
  2. Notable Primary completion date: Sep 2024 to Sep 2026
    • Study completion date: Sep 2034 to Sep 2036
    v6
  3. Minor Site details revised at 1 of 2 sitesv5
  4. Minor Start date changed from estimate of Mar 2021 to Apr 27, 2021
    • Site contacts updated at 1 of 2 sites
    v3
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised at 2 of 2 sites
    v2
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Overall response rate
Timeframe: Up to 16 weeks

Secondary (2)

Incidence of treatment-related adverse events as assessed by CTCAE v5.0 and dose reductions (safety and tolerability)
Correlation between TP53 mutation assessed by sequencing of tumor DNA and overall response

Arms and interventions

Sequential ifosfamide and doxorubicinExperimental

Four cycles ifosfamide 9 g/m2 and four cycles doxorubicin 80 mg/m2. Each cycle has a duration of 14 days.

Drugs: Ifosfamide, Doxorubicin

Sites

2 sites in 1 country